Efficacy and Safety of Obinutuzumab in Adolescents with Active Lupus Nephritis: Primary Results from POSTERITY, a Phase II Global Trial (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-OR073; Pres time: Oct 24, 2026; 04:30 PM - 04:42 PM; Location: Four Seasons Ballroom 2, Convention Center; P2, P3 | "Selected secondary endpoints included CRR at Week 24 and Week 52, CRR at Week 76 with successful prednisone taper (≤7.5 mg/day from Weeks 64–76), overall renal response at Week 76, and time to onset of CRR over 76 weeks. OBI was well tolerated; safety findings were consistent with the known profile in adults, with no new safety signals identified. Conclusion These results in a dedicated adolescent cohort with active class III or IV ± V LN support OBI as a potential targeted intervention in a population with limited treatment options."
Clinical • Late-breaking abstract • P2 data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Marina Vivarelli; Deborah Levy; Gabriel Vega Cornejo; Maria Teresa Terreri; Aleksandra Zurowska; Adolfina Elizabeth Zuta; Joan Calzada-Hernández; Julien Hogan; Sandra Enciso-Peláez; Agustin Remesal; Louise Oni; Peiqing Yu; Felix Erblang; Olga Mitrofanova; William Franklin Pendergraft; Patricia B. Lehane
|